Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease

Size: px
Start display at page:

Download "Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease"

Transcription

1 The American Journal of Medicine (2006) 119, CLINICAL RESEARCH STUDY Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease Abhijit V. Kshirsagar, MD, MPH, a Myra Carpenter, PhD, b,c Heejung Bang, PhD, d Sharon B. Wyatt, RN, CANP, PhD, e Romulo E. Colindres, MD, MSPH a a UNC Kidney Center, School of Medicine, b Department of Epidemiology, c Collaborative Studies Coordinating Center, Department of Biostatistics, School of Public Health, University of North Carolina at Chapel Hill; d Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College, Cornell University, New York, NY; and e Schools of Nursing and Medicine and Jackson Heart Study Examination Center, University of Mississippi Medical Center, Jackson. ABSTRACT PURPOSE: Research on the risk of cardiovascular disease among individuals with prehypertension (blood pressure 120/80 to 139/89 mm Hg) is incomplete. Additional information among individuals with a high risk of cardiovascular disease complications may help to focus current and future efforts. SUBJECTS AND METHODS: We performed a prospective cohort analysis among 8960 middle-aged adults in the Atherosclerosis Risk in Communities (ARIC) study. The exposure variables were blood pressure levels: high normal blood pressure, systolic blood pressure mm Hg or diastolic blood pressure mm Hg; and normal blood pressure, systolic blood pressure mm Hg or diastolic blood pressure mm Hg. The outcome was incident cardiovascular disease defined as fatal/nonfatal coronary heart disease, cardiac procedure, silent myocardial infarction, or ischemic stroke. Subgroup analysis was performed among blacks, diabetics, individuals aged years, individuals with renal insufficiency, and among individuals with varying levels of low-density lipoprotein (LDL) cholesterol and body mass index (BMI). RESULTS: Compared with optimal blood pressure (systolic blood pressure 120 mm Hg and diastolic blood pressure 80 mm Hg), the relative risk (RR) of cardiovascular disease for high normal blood pressure was 2.33 (95% confidence interval [CI], ), and RR for normal blood pressure was 1.81 ( ); among blacks: RR for high normal blood pressure was 3.29 (95% CI, ); among diabetics: RR for high normal blood pressure 4.10 (95% CI, ); age years: RR for high normal blood pressure 2.41 (95% CI, ) among individuals with renal insufficiency: RR for high normal blood pressure was 1.90 (95% CI, ); among individuals with BMI 30 kg/m 2 :RRfor high normal blood pressure was 3.56 (95% CI, ); and among individuals with LDL 160 mg/dl, RR for high normal blood pressure was 1.85 (95% CI, ). CONCLUSIONS: Individuals with prehypertensive levels of blood pressure have an increased risk of developing cardiovascular disease relative to those with optimal levels. The association is pronounced among blacks, among individuals with diabetes mellitus, and among those with high BMI Elsevier Inc. All rights reserved. KEYWORDS: Prehypertension; Cardiovascular disease; Cohort study In 2003, the Seventh Joint National Committee (JNC 7) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure introduced a new and distinct category of blood pressure, prehypertension. 1 The committee recommended close follow-up and possible intervention for individuals with Requests for reprints should be addressed to Abhijit V. Kshirsagar MD MPH, CB Burnett-Womack Hall, Chapel Hill, NC sagar@med.unc.edu systolic blood pressure mm Hg or diastolic blood pressure mm Hg 1,2 because of an elevated risk of incident cardiovascular disease. 3,4 The designation of prehypertension, blood pressure levels usually considered normal, has raised concerns. The new category will swell the ranks of individuals targeted for blood pressure modification by millions in the United States alone. The influx would strain the infrastructure of all but the wealthiest nations. More importantly, the prehyperten /$ -see front matter 2006 Elsevier Inc. All rights reserved. doi: /j.amjmed

2 134 The American Journal of Medicine, Vol 119, No 2, February 2006 CLINICAL SIGNIFICANCE sive group represents a heterogeneous cohort of individuals with varying risk profiles for cardiovascular disease; undoubtedly, some individuals would be treated unnecessarily with pharmacologic agents. These concerns may help to explain the reluctance of clinicians and societies to adopt the recommendations of the JNC 7. 5,6 Quantifying the impact of prehypertension in groups with a high risk for cardiovascular disease complications may help to focus efforts. There is sparse information for individuals with diabetes mellitus, individuals with renal insufficiency, overweight/obese individuals, individuals with hypercholesterolemia, minorities, or for individuals with relatively advanced age. We therefore investigated the association of prehypertension levels of blood pressure with the risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. This large, biracial cohort of middle-aged men and women with varied demographic and medical characteristics allowed us to examine the association of prehypertension levels of blood pressure with cardiovascular disease in several subgroups of interest. METHODS Study Participants The ARIC study is a prospective epidemiologic study of the etiology and natural history of atherosclerotic diseases in men and women. 7 Participants were aged 45 to 64 years at the baseline examination (Visit 1) conducted from This population-based cohort was recruited from Forsyth County, NC; Jackson, Miss; suburbs of Minneapolis, Minn; and, Washington County, Md. The present investigation was restricted to black or white participants without prevalent coronary heart disease based on electrocardiogram (ECG) evidence or self-report of physician diagnosis and without self-reported physician diagnosis of stroke at baseline. Individuals at the initial examination with diastolic blood pressure 90 mm Hg or systolic blood pressure 140 mm Hg, or who reported taking a medication to control hypertension, or missing eligibility data were excluded. Data Collection Three follow-up examinations (Visits 2, 3, and 4) were completed at approximately 3-year intervals following Visit 1. Visit 4 concluded in January Annual telephone contacts that include follow-up for incident cardiovascular events have been conducted since the baseline examination and are continuing. Prehypertension is associated with an elevated risk of cardiovascular disease, especially coronary heart disease. The risk of cardiovascular disease is more pronounced among certain groups with prehypertension diabetics, African Americans, and obese individuals. Intervention trials are urgently needed to quantify the extent of any potential benefit of therapy among prehypertensive individuals. Study Variables Blood pressures were measured utilizing standardized procedures 8 by trained and certified technicians at each of the 4 ARIC examinations. A random-zero mercury manometer was used to measure blood pressures after the participant had been sitting quietly for 5 minutes. Three hierarchal categories of blood pressure were formed according to JNC 6 recommendations. 9 Systolic and diastolic pressures were independently classified as optimal, normal, or high normal. An individual s blood pressure was then classified as the worse of these two categories. For example, a reading of 130/60 mm Hg yields a high normal systolic pressure and an optimal diastolic pressure resulting in an overall classification of high normal. High normal blood pressure: 130 mm Hg systolic blood pressure 140 mm Hg or 85 mm Hg diastolic blood pressure 90 mm Hg. Normal blood pressure: 120 mm Hg systolic blood pressure 130 mm Hg or 80 mm Hg diastolic blood pressure 85 mm Hg. Optimal blood pressure: systolic blood pressure 120 mm Hg and diastolic blood pressure 80 mm Hg. Race identification was reported by the participant or a member of the participant s household using categories (white, black, American Indian/Alaskan Indian, or Asian/ Pacific Islander). Certified technicians adhering to standardized procedures drew and processed blood. 10 Fasting glucose (hexokinase method), fibrinogen (thrombin-time titration method), von Willebrand factor (vwf, ELISA procedure), and highdensity lipoprotein cholesterol (HDL, enzymatic method) were measured by central laboratories. White blood cell count (WBC, by Coulter counters) was measured by laboratories local to the examination sites. Low-density lipoprotein cholesterol (LDL) 11 was calculated. Categories of LDL cholesterol were based on National Cholesterol Education Program (NCEP) guidelines. 12 Serum creatinine concentration was determined by the modified kinetic Jaffe method at a central laboratory. A correction constant of 0.24 mg/dl was subtracted from each measured value of serum creatinine concentration in this analysis to correct for noncreatinine chromagens. 13 Renal function was estimated by the Cockcroft-Gault creatinine clearance (CrCl), 14 normalized to 1.73 m Renal insufficiency was defined as CrCl less than 90 ml/min/1.73 m 2, and further categorized by severity according to the recently published guidelines for classification of chronic kidney disease. 16 Creatinine clearance ml/min/1.73m 2 is based on Stage 2 chronic kidney disease, and CrCl 60 ml/min/1.73m 2 is based on stage 3 or higher chronic kidney disease. Body mass index was computed using weight and height collected by trained and certified staff using standardized pro-

3 Kshirsagar et al Prehypertension and CVD 135 cedures and equipment. Categories of body mass index (BMI) were based on Federal guidelines. 17 The sport index for physical activity was derived from a physical activity interview developed by Baecke and colleagues. 18 The sport index reflects frequency, duration, and intensity of reported sport activities augmented by information on leisure time physical activity and sweating. Cholesterol-lowering and anti-hypertensive medication use reflected medications taken during the 2 weeks prior to the examination. Education level was self-reported. Diabetic status was defined based on a fasting (8 or more hours) glucose of 126 mg/dl, or nonfasting glucose of 200 mg/dl, self-reported physician s diagnosis of diabetes, or use of an antidiabetic medication during the 2 weeks prior to the examination. Cigarette smoking status was classified as either current, former, or never, based on self-report. Outcomes All participant hospitalizations occurring after the baseline examination were reviewed systematically for cardiovascular outcomes. Hospitalizations were identified from two information sources participant self-report and review of discharge lists prepared by area hospitals. Hospital medical records were reviewed and ones meeting specified criteria for possible cardiovascular disease were abstracted in detail. Incident cardiovascular disease was defined as the occurrence of either incident coronary heart disease or incident ischemic stroke. Procedures for ascertainment of incident coronary heart disease and for ascertainment and classification of ischemic stroke 23 are published elsewhere. Statistical Analyses Cox proportional hazards regression was used to estimate the hazards ratio (HR) or relative risk between blood pressure levels and cardiovascular disease event rate. 24 The relative risk between blood pressure levels and incident coronary heart disease or incident stroke was also estimated with Cox proportional hazards regression. Follow-up time was defined as the number of days from Visit 1 to the date of the first occurrence of cardiovascular disease as defined previously, death, last contact, or December 31, We treated all the risk factors, including blood pressure, as fixed at baseline as well as time-varying unless information was available only at baseline. Time-varying covariates can capture the dynamic nature of changes in covariate status. The time-varying covariates included systolic blood pressure, diastolic blood pressure, diabetic status, HDL cholesterol, LDL cholesterol, smoking status, BMI, cholesterol-lowering medication use, and sport index. Although the resulting HRs from the analysis using fixed covariates, as expected, were slightly attenuated, the estimates from both analyses were highly consistent. Thus, we decided to present the results from the analysis allowing covariates to be time-dependent. For constructing time-varying covariates, we carried over the value from the previous visit, if the respective information was missing or not measured at the subsequent visit. A participant s data was censored from analysis at the date of the visit prior to the one at which they reported having started taking an antihypertensive medication. For example, if an individual reported the use of blood pressure medications at Visit 3, he/she was excluded from analysis starting at Visit 2. We expected the exclusion of these individuals, who likely had a heightened risk profile for cardiovascular disease, to bias the results toward the null hypothesis. Models included potential confounding variables sequentially. An initial model adjusted for key demographic variables (sex, age, race, and study site). Traditional risk factors for cardiovascular disease (BMI, smoking status, diabetes mellitus, LDL cholesterol, HDL cholesterol, cholesterol-lowering medication use, physical activity, and education level), in addition to available markers of inflammation (fibrinogen, vwf, and white blood cells) were controlled in the next model. We repeated the analyses for the subgroups. The Kaplan-Meier method was used to estimate the (unadjusted) risk of cardiovascular disease up to about 14 years, stratified by blood pressure status at baseline. 25 All analyses were performed using SAS statistical software (SAS Institute Inc., Cary, NC), and the type I error of 5% with a 2-sided hypothesis was used. RESULTS The study population consisted of 8960 middle-age men and women after the necessary exclusion of individuals with baseline cardiovascular disease and hypertension (Figure 1). The majority of individuals in the study population had blood pressure in the optimal range (n 5622), followed by normal blood pressure (n 2059), and high normal blood pressure (n 1279). The numbers of individuals that comprise each subgroup vary from approximately 600 diabetics to nearly 4000 individuals with renal insufficiency. Of the cohort of 8960 individuals at baseline, 8332 (93%) completed Visit 2, 7671 (86%) completed Visit 3, and 7095 (79%) completed the final evaluation at Visit 4. At baseline there were important trends in demographic and medical characteristics by category of blood pressure (Table 1). Individuals with high normal blood pressure had a greater prevalence of traditional risk factors for cardiovascular disease compared with the optimal blood pressure group, including male sex, nonwhite race, diabetes mellitus, and others. Risk factor measures for individuals in the normal blood pressure group generally fell between values for the optimal blood pressure and high normal blood pressure groups. The proportion of current smokers and renal function did not vary meaningfully across the 3 levels of blood pressure. The incidence of cardiovascular disease increased monotonically across the 3 categories of blood pressure level (Figure 2 and Table 2) for the entire cohort. During the follow-up period (average 11.6 years) there were a total of 772 new cardiovascular disease events. The vast majority of these events were related to coronary heart disease. Individuals with diabetes mellitus had the highest proportion of cardiovascular disease events, followed by individuals with LDL 160 mg/dl, and age years. Events related to coronary heart disease events comprised the majority of cardiovascular disease events (data presented in Appendix). Normal blood pressure and high normal blood pressure were each associated with an increased risk for cardiovascular disease compared with optimal blood pressure (Table 3). Among individuals with normal blood pressure, the hazards

4 136 The American Journal of Medicine, Vol 119, No 2, February 2006 Figure 1 Study population. *Not mutually exclusive. NBP normal blood pressure; HNBP high normal blood pressure. ratio for incident cardiovascular disease compared with the optimal group was 1.81 (95% confidence interval [CI], ) after adjustment for demographic factors, and remained significant after further adjustment. In the high normal blood pressure group, the hazards ratio for incident cardiovascular disease compared with optimal blood pressure was 2.49 (95% CI, ) after adjustment for baseline demographic factors, and remained significant after adjustment for traditional risk factors. Both the normal blood pressure and high normal blood pressure groups were associated with incident coronary heart disease. The point estimates for incident stroke for the normal blood pressure and high normal blood pressure groups compared with optimal blood pressure were significant only with the demographic model for normal blood pressure, but the number of incident stroke events was relatively small (n 128). Table 1 Baseline demographic and medical characteristics of the study population by blood pressure Optimal blood pressure Normal blood pressure High normal blood pressure Variable n 5622 n 2059 n 1279 Age (years) 53 (6) 54 (6) 55 (6) Sex (% male) 42% 51% 51% Race (% white) 86% 77% 72% Diabetes mellitus 5% 7% 10% Education ( high school) 16% 21% 23% Current smoker 28% 25% 24% Systolic BP (mm Hg) 106 (8) 123 (4) 132 (5) Diastolic BP (mm Hg) 67 (7) 75 (7) 79 (8) LDL cholesterol (mg/dl) 134 (38) 137 (38) 137 (38) HDL cholesterol (mg/ll) 53 (17) 52 (17) 53 (18) Serum glucose (mg/dl) 101 (28) 105 (31) 108 (33) CrCl ml/min/1.73m 2 95 (19) 95 (20) 96 (21) Fibrinogen mg/dl 291 (60) 299 (62) 299 (63) vwf % 111 (43) 115 (46) 117 (45) WBC count 10 3 cells/mm (1.9) 6.1 (1.8) 6.0 (1.8) BMI 26.0 (4.2) 27.5 (5.0) 28.1 (5.3) Sport index 2.5 (0.8) 2.5 (0.8) 2.4 (0.8) Cholesterol medication usage 1.7% 2.2% 2.2% Mean (standard deviation) for continuous variables. BP blood pressure; CrCl creatinine clearance; vwf von Willebrand factor; WBC white blood cell.

5 Kshirsagar et al Prehypertension and CVD 137 Figure 2 Incidence of CVD by blood pressure level. The associations of prehypertension levels of blood pressure with incident cardiovascular disease among the subgroups of interest are presented in Table 4. Normal and high normal blood pressure were both significantly associated with incident cardiovascular disease among all subgroups. The majority of the cardiovascular disease events were related to coronary heart disease rather than stroke. Analysis of the outcome by coronary heart disease or stroke revealed that the hazards ratios were significant for coronary heart disease alone, and not for stroke (data not shown). The point estimates for cardiovascular disease were especially high among blacks, diabetic individuals, individuals with LDL mg/dl, and BMI 30 kg/m 2. Among blacks, the Hazard Ratio for cardiovascular disease was 3.29 for high normal blood pressure compared with optimal blood pressure after full adjustment. Among individuals with diabetes mellitus, normal blood pressure was associated with over a 2-fold greater risk of incident cardiovascular disease compared with optimal blood pressure after adjustment for demographic and traditional risk factors; furthermore, high normal blood pressure was associated with a 4-fold increase for new cardiovascular disease events compared with the optimal blood pressure group. Among individuals with LDL cholesterol mg/ dl, high normal blood pressure was associated with over a 2-fold increase in cardiovascular disease compared with optimal levels of blood pressure. Finally, among individuals with BMI 30 kg/m 2, normal blood pressure and high normal blood pressure were associated with a more than a 3-fold increase in cardiovascular disease compared with optimal blood pressure. Table 2 Incident CVD, CHD, and stroke events by blood pressure category for the entire cohort (proportion in parentheses) Optimal blood pressure Normal blood pressure High normal blood pressure Total CVD 393/5622 (0.07) 221/2059 (0.11) 158/1279 (0.12) 772/8960 (0.09) CHD 343/5622 (0.06) 192/2059 (0.09) 136/1279 (0.11) 671/8960 (0.07) Stroke 65/5622 (0.01) 38/2059 (0.02) 25/1279 (0.02) 128/8960 (0.01) CVD cardiovascular disease; CHD coronary heart disease.

6 138 The American Journal of Medicine, Vol 119, No 2, February 2006 Table 3 Hazards ratio* of CVD relative to the optimal blood pressure group by level of blood pressure (95% CI) Model Optimal blood pressure Normal blood pressure High normal blood pressure Demographic CVD ( ) 2.49 ( ) CHD ( ) 2.64 ( ) Stroke ( ) 1.43 ( ) Traditional CVD ( ) 2.33 ( ) CHD ( ) 2.44 ( ) Stroke ( ) 1.31 ( ) Demographic model: center, age, race, sex. Traditional model: demographic model variables and body mass index, diabetes mellitus, smoking status, low-density lipoproteins, high-density lipoproteins, education level, sport index, cholesterol lowering medication use, fibrinogen, von Willebrand factor, white blood cell count (WBC). *Time-dependent covariates were used. CVD cardiovascular disease; CHD coronary heart disease. DISCUSSION Previous classification schemes had emphasized a threshold for intervention to reduce cardiovascular disease complications at a blood pressure 140/90 mm Hg for most individuals. Clinical practice patterns have generally reflected these recommendations. The results of our analysis lend additional support for the new JNC 7 recommendation: individuals with prehypertension require close follow-up at the very least, and probably, lifestyle modification. Furthermore, our findings suggest that focusing efforts on certain groups of individuals with a high risk of cardiovascular complications may be warranted. After adjustment for demographic and traditional risk factors, normal blood pressure and high normal blood pressure were associated with a 69% and 133% greater risk of incident cardiovascular disease, respectively, compared with optimal blood pressure. Importantly, coronary heart disease events comprised the majority of the cardiovascular disease outcomes. The overall number of stroke events was small, and prevent us from drawing any meaningful inferences. Furthermore, subgroup analysis revealed important heterogeneity of the relationship of prehypertension and incident cardiovascular disease events. The point-estimates were especially high among blacks, individuals with diabetes mellitus, high BMI, Table 4 Hazards ratio* of CVD relative to optimal blood pressure for groups with high baseline risk (95% CI) Model Normal blood pressure High normal blood pressure Demographic Blacks 2.37 ( ) 3.61 ( ) Diabetics 2.91 ( ) 3.90 ( ) CrCl ml/min/1.73m ( ) 1.99 ( ) Age years 1.79 ( ) 2.51 ( ) LDL mg/dl 1.80 ( ) 3.24 ( ) mg/dl 1.54 ( ) 2.37 ( ) 160 mg/dl 1.60 ( ) 1.83 ( ) BMI kg/m ( ) 2.10 ( ) kg/m ( ) 2.36 ( ) 30 kg/m ( ) 3.38 ( ) Traditional Blacks 2.09 ( ) 3.29 ( ) Diabetics 2.36 ( ) 4.10 ( ) CrCl ml/min/1.73m ( ) 1.90 ( ) Age years 1.68 ( ) 2.41 ( ) LDL mg/dl 1.59 ( ) 2.66 ( ) mg/dl 1.54 ( ) 2.42 ( ) 160 mg/dl 1.55 ( ) 1.85 ( ) BMI kg/m ( ) 2.09 ( ) kg/m ( ) 2.14 ( ) 30 kg/m ( ) 3.56 ( ) Demographic model: center, age, sex, and race when appropriate. Traditiona model: demographic model variables and body mass index, smoking status, low-density lipoproteins, high-density lipoproteins, education level, sports index, cholesterol lowering medication use and diabetes mellitus, fibrinogen, von Willebrand factor, white blood cell count (WBC). *Time-dependent covariates were used. LDL low-density lipoprotein; BMI body mass index; CrCL creatinine clearance.

7 Kshirsagar et al Prehypertension and CVD 139 and relatively low LDL-cholesterol values. Individuals with mild renal insufficiency, with higher age, or with moderately high levels of LDL-cholesterol demonstrated a 60-90% greater risk of cardiovascular disease for prehypertension levels of blood pressure compared with the optimal blood pressure group. The potential impact of prehypertension is large. The population attributable risk (PAR) represents the proportion of the disease in the whole population that would be prevented if the risk factor were eliminated. For the entire cohort, this would amount to almost 30% of new cardiovascular events 13.7 % from the normal group, and 16.0 % from the high normal group. Among blacks, the elimination of normal and high normal blood pressure would prevent 24.1% and 33.4% of new cardiovascular events, respectively. For persons with LDL cholesterol mg/dl, the corresponding PAR is estimated as 11.5% for the normal group, and 19.2% for high normal. Nearly 26% and 40% of new cardiovascular events might be prevented by eliminating normal blood pressure and high normal blood pressure, respectively, among diabetic individuals. Among the group of individuals with BMI 30 kg/m 2, 38% and 36% of new cardiovascular events could be prevented with the elimination of normal and high normal blood pressure, respectively. These estimates may be understating the true magnitude of prehypertension given the rising prevalence of obesity. The results of the present analysis also reiterate the importance of increased blood pressure as a risk factor for cardiovascular disease Many causative/predictive factors influence the clinical occurrence of cardiovascular disease, among which are the interplay of dyslipidemia, diabetes mellitus, hypertension, smoking, and other (some yet-to-be determined) host and environmental factors. In our analysis, adjustment for most of these risk factors did not greatly attenuate the relationship of blood pressure and cardiovascular disease. Recently, there has been debate about whether traditional risk factors for cardiovascular disease hold for individuals with renal insufficiency. 32,33 Unique physiologic changes occur with the onset of renal insufficiency; thus kidneyspecific risk factors such as osteodystrophy, anemia, uremic toxins, and others have been proposed to account for the high burden of cardiovascular disease. 34,35 Furthermore, among individuals with advanced kidney disease, neither systolic blood pressure nor diastolic blood pressure elevation was associated with cardiovascular disease. 36 The current analysis suggests that even modestly elevated blood pressure remains an important risk factor for cardiovascular disease among individuals with renal insufficiency. There was a stepwise increase in risk across the 3 categories of blood pressure, although the point estimates were smaller among individuals with renal insufficiency than the point estimates for the entire cohort. The magnitude of effect was surprisingly large in a group of individuals with relatively low levels of LDL cholesterol. This finding was not an effect of small sample size or a small number of cardiovascular disease events (see Appendix). Speculatively, at lower levels of LDL cholesterol, the relative effect of other risk factors for cardiovascular disease (such as blood pressure) may predominate. Additional study is necessary to confirm this observation. The current analysis adds to existing information. Previous studies have also demonstrated a similar relationship of prehypertension levels of blood pressure and cardiovascular disease. In one analysis from the Framingham cohort, men and women with systolic blood pressure mm Hg or diastolic blood pressure mm Hg have a 1.6- and 2.5-fold increased risk of fatal and nonfatal cardiovascular disease, respectively, compared with those with blood pressure at or below 120/80 mm Hg. 4 Yet, the Framingham cohort includes few minorities, and the analysis did not investigate subgroups included in the present study. Another study demonstrated that each increment of 20 mm Hg systolic blood pressure or 10 mm Hg diastolic blood pressure doubles the risk of cardiovascular disease death across the entire range of blood pressure, including blood pressure in the prehypertension range. 3 Yet this large meta-analysis may have underestimated the magnitude of clinically relevant cardiovascular disease by using only fatal cardiovascular disease as the outcome of measure. This study should be evaluated in the context of the following limitations. Despite the strong and consistent association of prehypertension with elevated risk of cardiovascular disease, it is not possible to determine whether the elevated risk was solely attributable to the blood pressure. A modest elevation of blood pressure above optimal is closely associated with multiple rheologic, hemodynamic, and metabolic abnormalities; many of these abnormalities independently increase the risk of cardiovascular disease. 37 Two, the age range of the ARIC study was years at baseline, or middle-age. With the aging population, information on the relationship of prehypertension and cardiovascular disease among elderly individuals would be pertinent. In summary, prehypertension levels of blood pressure are clearly associated with a significant increase in incident cardiovascular disease. The effect of prehypertension is especially pronounced among blacks, individuals with diabetes mellitus, elevated BMI, and relatively low LDL cholesterol levels suggesting that clinicians may consider lowering the threshold for action among these groups. These findings may also offer compelling evidence for screening and early detection in vulnerable groups. Randomized intervention studies are needed to quantify the extent of any potential benefit of therapy among individuals with blood pressure levels usually considered normal. ACKNOWLEDGMENTS The Atherosclerosis Risk in Communities Study (ARIC) is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC , N01-HC-55021, and N01-HC Dr. Carpenter s effort is supported by the Jackson Heart Study, National Heart, Lung, and Blood Institute and National Center for Minority Health and Health Disparities contract N01-HC Dr. Wyatt s effort is supported by the Jackson Heart Study, National Heart, Lung, and Blood Institute and the National Center for Minority Health and Health Disparities contract N01-HC The authors thank the staff and participants of the ARIC study for their important contributions.

8 140 The American Journal of Medicine, Vol 119, No 2, February 2006 Appendix Incident cardiovascular disease, coronary heart disease, and stroke events by blood pressure category for the subgroups of interest (risk in parentheses) Optimal blood pressure Normal blood pressure High normal blood pressure Total Age years n 3610 n 1087 n 630 n 5327 CVD 197 (0.055) 99 (0.091) 67 (0.106) 363 (0.068) CHD 183 (0.051) 88 (0.081) 59 (0.094) 330 (0.062) Stroke 18 (0.005) 14 (0.013) 9 (0.014) 41 (0.008) Age years n 2012 n 972 n 649 n 3633 CVD 196 (0.097) 122 (0.126) 91 (0.140) 409 (0.113) CHD 160 (0.080) 104 (0.107) 77 (0.119) 341 (0.094) Stroke 47 (0.023) 24 (0.025) 16 (0.025) 87 (0.024) Blacks n 809 n 482 n 363 n 1654 CVD 36 (0.044) 29 (0.060) 37 (0.102) 102 (0.062) CHD 25 (0.031) 24 (0.050) 29 (0.080) 78 (0.047) Stroke 14 (0.017) 7 (0.015) 9 (0.025) 30 (0.018) Whites n 4813 n 1577 n 916 n 7306 CVD 357 (0.074) 192 (0.122) 121 (0.132) 670 (0.092) CHD 318 (0.066) 168 (0.107) 107 (0.117) 593 (0.081) Stroke 51 (0.011) 31 (0.020) 16 (0.017) 98 (0.013) Diabetics n 303 n 152 n 131 n 586 CVD 61 (0.201) 45 (0.296) 36 (0.275) 142 (0.242) CHD 53 (0.175) 41 (0.270) 33 (0.252) 127 (0.217) Stroke 14 (0.046) 7 (0.046) 4 (0.031) 25 (0.043) Nondiabetic n 5291 n 1897 n 1133 n 8321 CVD 331 (0.063) 176 (0.093) 121 (0.107) 628 (0.075) CHD 289 (0.055) 151 (0.080) 102 (0.090) 542 (0.065) Stroke 51 (0.010) 31 (0.016) 21 (0.019) 103 (0.012) CrCl ml/min/1.73m 2 n 2381 n 893 n 548 n 3822 CVD 177 (0.074) 96 (0.108) 75 (0.137) 348 (0.091) CHD 152 (0.064) 81 (0.091) 61 (0.111) 294 (0.077) Stroke 33 (0.014) 17 (0.019) 15 (0.027) 65 (0.017) CrCl 90 ml/min/1.73m 2 n 3155 n 1123 n 705 n 4983 CVD 206 (0.065) 121 (0.108) 81 (0.115) 408 (0.082) CHD 183 (0.058) 108 (0.096) 74 (0.105) 365 (0.073) Stroke 29 (0.009) 20 (0.018) 9 (0.013) 58 (0.012) LDL 99 n 960 n 318 n 184 n 1462 CVD 37 (0.039) 18 (0.057) 9 (0.049) 64 (0.044) CHD 30 (0.031) 13 (0.041) 4 (0.022) 47 (0.032) Stroke 11 (0.011) 5 (0.016) 5 (0.027) 21 (0.014) LDL n 1693 n 587 n 380 n 2660 CVD 75 (0.044) 47 (0.080) 52 (0.137) 174 (0.065) CHD 61 (0.036) 39 (0.066) 45 (0.118) 145 (0.055) Stroke 18 (0.011) 11 (0.019) 8 (0.021) 37 (0.014) LDL n 1598 n 606 n 357 n 2561 CVD 126 (0.079) 75 (0.124) 47 (0.132) 248 (0.097) CHD 114 (0.071) 66 (0.109) 41 (0.115) 221 (0.086) Stroke 15 (0.009) 12 (0.020) 7 (0.020) 34 (0.013) LDL 160 n 1287 n 504 n 323 n 2114 CVD 149 (0.116) 74 (0.147) 47 (0.146) 270 (0.128) CHD 132 (0.103) 67 (0.133) 43 (0.133) 242 (0.114) Stroke 21 (0.016) 8 (0.016) 4 (0.012) 33 (0.016) BMI 18.5 n 52 n 18 n 13 n 83 CVD 3 (0.058) 2 (0.111) 4 (0.308) 9 (0.108) CHD 3 (0.058) 1 (0.056) 4 (0.308) 8 (0.096) Stroke 1 (0.019) 1 (0.056) 0 (0.000) 2 (0.024) BMI n 2514 n 622 n 381 n 3517 CVD 131 (0.052) 52 (0.084) 43 (0.113) 226 (0.064) CHD 116 (0.046) 47 (0.076) 36 (0.094) 199 (0.057) Stroke 19 (0.008) 6 (0.010) 7 (0.018) 32 (0.009) BMI n 2178 n 911 n 493 n 3582 CVD 197 (0.090) 114 (0.125) 63 (0.128) 374 (0.104) CHD 175 (0.080) 99 (0.109) 51 (0.103) 325 (0.091) Stroke 29 (0.013) 20 (0.022) 12 (0.024) 61 (0.017) BMI 30 n 877 n 508 n 390 n 1775 CVD 62 (0.071) 53 (0.104) 48 (0.123) 163 (0.092) CHD 49 (0.056) 45 (0.089) 45 (0.115) 139 (0.078) Stroke 16 (0.018) 11 (0.022) 6 (0.015) 33 (0.019)

9 Kshirsagar et al Prehypertension and CVD 141 References 1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360: Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001; 345: European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21: Weber MA. Yet more hypertension guidelines: what do they add? J Hypertens. 2003;21: ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129: ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol Manual 11: Sitting Blood Pressure. Chapel Hill, NC: Collaborative Studies Coordinating Center; The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157: ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol Manual 7: Blood Collection and Processing, Version 1.1. Chapel Hill, NC: Collaborative Studies Coordinating Center; Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16: Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17: Work Group and Evidence Review Team: Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis. 2002;39(suppl 1):S46-S Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults The Evidence Report. National Institutes of Health. Obes Res. 1998;6(suppl 2):51S-209S. 18. Baecke JAH, Burema J, Frijters JER. A short questionnaire for the measurement of habitual physical activity in epidemiologic studies. Am J Clin Nutr. 1982;36: ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol Manual 3. Surveillance Component Procedures. Chapel Hill, NC: Collaborative Studies Coordinating Center; Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to N Engl J Med. 1998;339: Rosamond WD Folsom AR Chambless LE Wang CH Coronary heart disease trends in four United States communities The Atherosclerosis Risk in Communities (ARIC) study Int J Epidemiol. 30 suppl S17-S White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years experience. J Clin Epidemiol. 1996;49: Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30: Therneau TM, Gambsch P. Modeling Survival Data: Extending the Cox Model. New York: Springer; Kaplan EL, Meier P. Non-parametic estimation from incomplete observations. J Am Stat Assoc. 1958: Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet. 1998;352: Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275: MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335: Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152: Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153: van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000; 342: Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61: Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291: Jaradat MI, Molitoris BA. Cardiovascular disease in patients with chronic kidney disease. Semin Nephrol. 2002;22: Paparello J, Kshirsagar A, Batlle D. Comorbidity and cardiovascular risk factors in patients with chronic kidney disease. Semin Nephrol. 2002;22: Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58: Julius S. Borderline hypertension. Clin Exp Hypertens. 1999;21:

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION by PAUL E. DRAWZ, MD, MHS Submitted in partial fulfillment of the requirements for the degree of Master

More information

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized

More information

Chronic kidney disease (CKD) has received

Chronic kidney disease (CKD) has received Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

Type 2 diabetes is a significant risk factor for coronary

Type 2 diabetes is a significant risk factor for coronary Cardiovascular Events in Diabetic and Nondiabetic Adults With or Without History of Myocardial Infarction Chong Do Lee, EdD; Aaron R. Folsom, MD; James S. Pankow, PhD; Frederick L. Brancati, MD; For the

More information

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 N OVEMBER 1, 2001 NUMBER 18 IMPACT OF HIGH-NORMAL BLOOD PRESSURE ON THE RISK OF CARDIOVASCULAR DISEASE

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

CONTRIBUTING FACTORS FOR STROKE:

CONTRIBUTING FACTORS FOR STROKE: CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING

More information

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex

Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Cardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction

Cardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction Journal of the American College of Cardiology Vol. 48, No. 6, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.05.047

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Journal of the American College of Cardiology Vol. 57, No. 16, by the American College of Cardiology Foundation ISSN /$36.

Journal of the American College of Cardiology Vol. 57, No. 16, by the American College of Cardiology Foundation ISSN /$36. Journal of the American College of Cardiology Vol. 57, No. 16, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.041

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

A n aly tical m e t h o d s

A n aly tical m e t h o d s a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.

More information

YOUNG ADULT MEN AND MIDDLEaged

YOUNG ADULT MEN AND MIDDLEaged BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

The Framingham Risk Score (FRS) is widely recommended

The Framingham Risk Score (FRS) is widely recommended C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore

More information

Much of the United States adult population is at risk of

Much of the United States adult population is at risk of Absolute and Attributable Risks of Heart Failure Incidence in Relation to Optimal Risk Factors Aaron R. Folsom, MD; Kazumasa Yamagishi, MD, PhD; Atsushi Hozawa, MD, PhD; Lloyd E. Chambless, PhD; for the

More information

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01. NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic

More information

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153

S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening

More information

Atherosclerotic Disease Risk Score

Atherosclerotic Disease Risk Score Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program

More information

ARIC Manuscript Proposal # PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority: ARIC Manuscript Proposal # 1508 PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hemostatic markers and risk of atrial fibrillation: the Atherosclerosis Risk

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

Echocardiography analysis in renal transplant recipients

Echocardiography analysis in renal transplant recipients Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical

More information

Elevated blood pressure (BP) is a major modifiable risk factor

Elevated blood pressure (BP) is a major modifiable risk factor Blood Pressure in Adulthood and Life Expectancy With Cardiovascular Disease in Men and Women Life Course Analysis Oscar H. Franco, Anna Peeters, Luc Bonneux, Chris de Laet Abstract Limited information

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at Supplementary notes on Methods The study originally comprised 10,308 (3413 women) individuals who, at recruitment in 1985/8, were London-based government employees (civil servants) aged 35 to 55 years.

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative

More information

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis

Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*

Lucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1* Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

ARIC Manuscript Proposal #1233. PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority:

ARIC Manuscript Proposal #1233. PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority: ARIC Manuscript Proposal #1233 PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority: 1.a. Full Title: Subclinical atherosclerosis precedes type 2 diabetes in the ARIC study cohort

More information

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths ORIGINAL INVESTIGATION Effects of Prehypertension on Admissions and Deaths A Simulation Louise B. Russell, PhD; Elmira Valiyeva, PhD; Jeffrey L. Carson, MD Background: The Joint National Committee on Prevention,

More information

Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b

Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan R. Dyer, PhD a, Renwei Wang, MS a, Martha L. Daviglus, MD, PhD a, and Philip Greenland, MD a,b Risk Factor Burden in Middle Age and Lifetime Risks for Cardiovascular and Non-Cardiovascular Death (Chicago Heart Association Detection Project in Industry) Donald M. Lloyd-Jones, MD, ScM a,b, *, Alan

More information

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools. UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,

More information

Importance of a Patient s Personal Health History on Assessments of Future Risk of Coronary Heart Disease

Importance of a Patient s Personal Health History on Assessments of Future Risk of Coronary Heart Disease Importance of a Patient s Personal Health History on Assessments of Future Risk of Coronary Heart Disease Arch G. Mainous, III, PhD, Charles J. Everett, PhD, Marty S. Player, MD, MS, Dana E. King, MD,

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple

More information

Blood Pressure LIMBO How Low To Go?

Blood Pressure LIMBO How Low To Go? Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4

More information

Hypertension is an important global public

Hypertension is an important global public IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

The presence of cardiovascular disease risk factors, clinical

The presence of cardiovascular disease risk factors, clinical The Impact of JNC-VI Guidelines on Treatment Recommendations in the US Population Paul Muntner, Jiang He, Edward J. Roccella, Paul K. Whelton Abstract Using epidemiological and clinical trial evidence,

More information

Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities

Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities nature publishing group articles Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities Rachel P. Wildman 1, Aileen P. McGinn 1, Juan Lin 1, Dan Wang 1, Paul Muntner 2, Hillel W.

More information

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women

Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women European Heart Journal (2002) 23, 528 535 doi:10.1053/euhj.2001.2888, available online at http://www.idealibrary.com on Combined effects of systolic blood pressure and serum cholesterol on cardiovascular

More information

TEN-YEAR ABSOLUTE RISK ESTImates

TEN-YEAR ABSOLUTE RISK ESTImates ORIGINAL CONTRIBUTION CLINICIAN S CORNER Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Scan for Author Video Interview John T. Wilkins, MD, MS Hongyan Ning, MD, MS Jarett Berry, MD,

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table

More information

Protecting the heart and kidney: implications from the SHARP trial

Protecting the heart and kidney: implications from the SHARP trial Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

the U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations

the U.S. population, have some form of cardiovascular disease. Each year, approximately 6 million hospitalizations Cardioprotection: What is it? Who needs it? William B. Kannel, MD, MPH From the Department of Preventive Medicine and Epidemiology, Evans Department of Clinical Research, Boston University School of Medicine,

More information

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2

More information

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama

More information

Therapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines

Therapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines Therapeutic Lifestyle Changes and Drug Treatment for High Blood Cholesterol in China and Application of the Adult Treatment Panel III Guidelines Paul Muntner, PhD a,b,, Dongfeng Gu, MD c, Robert F. Reynolds,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

Hypertension affects approximately 65 million Americans,1 and is

Hypertension affects approximately 65 million Americans,1 and is Psychosocial Factors and Progression From Prehypertension to Hypertension or Coronary Heart Disease Marty S. Player, MD Dana E. King, MD, MS Arch G. Mainous III, PhD Mark E. Geesey, MS Department of Family

More information

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive

More information

KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64

KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64 211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Hypertension is a major risk factor for stroke in developed

Hypertension is a major risk factor for stroke in developed Prediction of Stroke by Self-Measurement of Blood Pressure at Home Versus Casual Screening Blood Pressure Measurement in Relation to the Joint National Committee 7 Classification The Ohasama Study Kei

More information

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2015.10.037

More information

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Long-term outcomes in nondiabetic chronic kidney disease

Long-term outcomes in nondiabetic chronic kidney disease original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

The incidence and prevalence of hypertension

The incidence and prevalence of hypertension Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George

More information

KEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.

KEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44. 28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,

More information